Alabama is currently home to 1232 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
NCT01790152
Recruiting
This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of dexrazoxane hydrochloride on cells. It may also help doctors understand how well patients respond to treatment.
Gender:
ALL
Ages:
All
Trial Updated:
04/16/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama
Conditions: Hodgkin Lymphoma in Remission, Leukemia in Remission, Lymphoblastic Lymphoma, Osteosarcoma, Recurrent Leukemia, Recurrent Lymphoma, Recurrent Malignant Neoplasm
Register for Updates
Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation
NCT06169735
Recruiting
The aim of this study is to determine if fluorescence with or without indocyanine green can facilitate safe and accurate thyroid and parathyroid surgery.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
04/15/2024
Locations: UAB Callahan Eye, Birmingham, Alabama
Conditions: Parathyroid Dysfunction, Adenoma
Register for Updates
Coaching Dementia Caregivers to Master Care-Resistant Behavior
NCT05098652
Recruiting
266 family caregivers will be randomly assigned to either immediate intervention or delayed intervention groups. All caregivers will complete baseline surveys and 3 weeks of daily diaries. The immediate intervention group will receive 12 weeks of CuRB-IT. They will complete 3 rounds of 3-week daily diaries followed by an intermittent survey at 12 week intervals for the next 33 weeks. The delayed intervention group will receive 12 weeks of attention, complete 1 round of 3-week daily diaries follo... Read More
Gender:
ALL
Ages:
Between 18 years and 95 years
Trial Updated:
04/15/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Care-resistant Behavior, Dementia
Register for Updates
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
NCT04042844
Recruiting
This is a double-blind, saline-controlled, and randomized study with blinded assessments using a single dose. Subjects that have a current diagnosis of chronic lumbar disc disease and meet eligibility criteria will be enrolled. Chronic lumbar disc disease is defined as back and/or radicular pain with degeneration of the disc confirmed by patient history, physical examination, and radiographic measures such as computed tomography (CT), magnetic resonance imaging (MRI), plain film, myelography, di... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
04/15/2024
Locations: Alabama Clinical Therapeutics, LLC, Birmingham, Alabama
Conditions: Lumbar Disc Disease
Register for Updates
Self-Collection of the Pap Smear as Agency: A Novel Way to Improve Refractory Low Cervical Cancer Screening Rates in Rural Alabama
NCT04093388
Recruiting
The purpose of the study is to find out if a self-administered (by the patient) Papanicolaou (Pap) smear is as accurate as a traditional Pap smear administered by a healthcare provider.
Gender:
FEMALE
Ages:
Between 21 years and 65 years
Trial Updated:
04/14/2024
Locations: Cahaba Medical Care - West End, Birmingham, Alabama
Conditions: Cervical Cancer
Register for Updates
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
NCT00736749
Recruiting
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
Gender:
ALL
Ages:
All
Trial Updated:
04/10/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama
Conditions: Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
Register for Updates
Maternal Newborn Health Registry
NCT01073475
Recruiting
The primary purpose of this population-based study is to quantify and understand the trends in pregnancy outcomes in defined low-resource geographic areas over time, in order to provide population-based data on stillbirths, neonatal and maternal mortality.
Gender:
ALL
Ages:
All
Trial Updated:
04/09/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Pregnancy Outcome Trends in Low-resource Geographic Areas
Register for Updates
Cognitive Training Intervention and Attitudes Towards Genetics
NCT03094026
Recruiting
A pilot study to evaluate feasibility of enrollment of patients in an intervention to improve neurocognitive function in hematopoietic cell transplantation (HCT) survivors using the cognitive training Lumosity program. In addition, patients' interest in receiving information regarding genetic risk of cognitive impairment post-HCT will be measured.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/08/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cognitive Impairment, Hematologic Neoplasms, Hematopoietic Cell Transplant
Register for Updates
A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)
NCT05685433
Recruiting
A prospective, multicenter, single-arm study to evaluate the safety and effectiveness of the eCoin® implanted tibial nerve stimulator in subjects with urgency urinary incontinence (UUI).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/06/2024
Locations: Urology Centers of Alabama, Homewood, Alabama
Conditions: Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
Register for Updates
ViTAA Registry Pre- and Post-Operative Monitoring for Endovascular Aortic Aneurysm Repair and Serial Monitoring for AAA
NCT05004051
Recruiting
This is a Prospective Registry study to collect imaging and clinical data both on patients with aortic aneurysm disease undergoing serial monitoring and on patients pre and post-endovascular repair, using ViTAA (The Sponsor) aortic mapping technology.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/06/2024
Locations: UAB - University of Alabama in Birmingham Hospital, Birmingham, Alabama
Conditions: Abdominal Aortic Aneurysms
Register for Updates
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
NCT04660760
Recruiting
This phase II trial studies the effect of the combination of ramucirumab and trifluridine/tipiracil or paclitaxel in treating patients with previously treated gastric or gastroesophageal junction cancer that has spread to other places in the body (advanced). Ramucirumab may damage tumor cells by targeting new blood vessel formation. Trifluridine/tipiracil is a chemotherapy pill and that may damage tumor cells by damaging their deoxyribonucleic acid (DNA). Paclitaxel may block cell growth by stop... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/29/2024
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Conditions: Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Unresectable Gastric Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
Register for Updates
JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
NCT05064540
Recruiting
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
Gender:
ALL
Ages:
21 years and above
Trial Updated:
03/28/2024
Locations: Huntsville Hospital, Huntsville, Alabama
Conditions: AAA, AAA - Abdominal Aortic Aneurysm
Register for Updates